Results 181 to 190 of about 3,545,288 (324)

Potential contribution of biomass gasification‐based technology in energy transition: a technical review coupled with bibliometric studies

open access: yesBiofuels, Bioproducts and Biorefining, EarlyView.
Abstract Biomass gasification technology has been extensively researched around the world; however, there is a need to evaluate the current research landscape and evolutionary direction of research in the broader context of energy transition. A systematic bibliometric analysis of the Web of Science database was performed for articles that fall within ...
Olasunkanmi Opeoluwa Adeoye   +5 more
wiley   +1 more source

Techno‐economic and environmental assessment of a hybrid renewable energy system for a date molasses factory in Iraq using HOMER Pro

open access: yesBiofuels, Bioproducts and Biorefining, EarlyView.
Abstract Iraq currently faces a significant electricity deficit estimated at approximately 18 000 MW, resulting in frequent and sometimes prolonged power outages that disrupt both economic activities and social life. The widening gap between energy supply and demand, combined with environmental concerns associated with fossil fuel consumption ...
Safaa Malik Abbas   +3 more
wiley   +1 more source

Market potential of biobased chemicals: a qualitative network analysis of adoption dynamics in South Africa’s bioeconomy

open access: yesBiofuels, Bioproducts and Biorefining, EarlyView.
Abstract The premise of a bioeconomy is the replacement of nonrenewable and unsustainable fossil‐derived resources and associated technologies with more sustainable alternatives. The adoption of biobased chemicals contributes toward the growth of a bioeconomy and is dependent on market and industry requirements.
Prisha Mandree   +2 more
wiley   +1 more source

Optimization of pharmaceutical research and development by early‐phase assessment of investigational medicinal products

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Small and mid‐sized pharmaceutical innovators often have limited in‐house health economics and market access expertise, and may struggle to align development strategies of investigational medicinal products with health system needs and payer expectations.
Zoltán Kaló   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy